# Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.

> **NCT00282620** · PHASE4 · UNKNOWN · sponsor: **Hartford Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Arrhythmia
- Quality of Life
- Hypomagnesemia

## Interventions

- **DRUG:** Magnesium L-lactate

## Key facts

- **NCT ID:** NCT00282620
- **Lead sponsor:** Hartford Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2007-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282620, "Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00282620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*